March 31, 2025

Health-Related QOL With Belzutifan vs Everolimus in Advanced Renal Cell Carcinoma

In a health-related quality of life (QOL) analysis reported in The Lancet Oncology, Powles et al found that belzutifan was associated with better QOL on patient-reported outcomes vs everolimus in pati...

The ASCO Post

March 25, 2025

Can a Urine Test Minimize Postoperative Scans for RCC Recurrence?

Researchers examined whether a urine test could accurately detect clear cell renal cell carcinoma recurrence at an early stage, according to findings presented at the European Association of Urology (...

The ASCO Post

November 22, 2023

Adjuvant Everolimus Improves Recurrence-Free Survival in Very High–Risk Renal Cell Carcinoma

A secondary analysis from the phase III SWOG S0931 EVEREST trial found that adjuvant everolimus given to patients with clear cell renal cell carcinoma at very high risk of recurrence after nephrectom...

The ASCO Post

January 30, 2024

Immune Checkpoint Inhibitor–Based Therapy May Have Comparative Efficacy in Black and White Patients With Metastatic Renal Cell Carcinoma

In a study presented at the 2024 ASCO Genitourinary Cancers Symposium, investigators compared the efficacy of immune checkpoint inhibitor–based therapies vs sunitinib as front-line treatment in Black ...

The ASCO Post

January 02, 2025

FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection

On December 27, 2024, the U.S. Food and Drug Administration approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult, solid tumor nivolumab indicatio...

The ASCO Post

December 27, 2023

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma

On December 14, the FDA approved an HIF-2α inhibitor for patients with advanced RCC following treatment with a PD-1 or PD-L1 inhibitor and a VEGF TKI.

The ASCO Post

June 23, 2023

In Case You Missed It: Brief Highlights From Studies Presented During AACR 2023

Presented here are some highlights of preliminary studies presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting. These presentations provide signals for the utility of a...

The ASCO Post

April 13, 2023

Belzutifan Plus Cabozantinib in Advanced Clear Cell Renal Cell Carcinoma Previously Treated With PD-1 or PD-L1 Inhibitors

In a U.S. phase II trial reported in The Lancet Oncology, Toni K. Choueiri, MD, and colleagues found that the combination of the hypoxia-inducible factor 2α inhibitor belzutifan and the VEGFR kinase i...

The ASCO Post

July 14, 2023

Novel Radiotracer May Accurately Detect and Differentiate Renal Cell Carcinomas

The new positron-emission tomography tracer zirconium (Zr)-89–DFO-girentuximab may accurately identify patients with clear cell renal cell carcinoma and differentiate the disease from other types of r...

The ASCO Post